
Can a Photograph Reveal Your Biological Age?
In a new study, published Thursday in The Lancet Digital Health, researchers trained artificial intelligence to estimate the biological ages of adults with cancer by analyzing photos of their faces. Study participants with younger estimates tended to fare better after treatment than those deemed older by A.I., researchers at Mass General Brigham found.
The findings suggest that people's biological age estimates are closely linked to their physical health, which could reflect their ability to survive certain treatments, the authors of the study said. And in the future, facial age analysis may become more useful than age alone in helping doctors make tough calls about their patients' treatment, they added.
Face-based aging tools have 'extraordinary potential' to help doctors quickly and inexpensively estimate how healthy their patients are, compared with existing tests, which use blood or saliva to measure chemical and molecular changes associated with aging, said William Mair, a professor of molecular metabolism at the Harvard T.H. Chan School of Public Health who was not involved in the study. While doctors usually visually estimate how healthy their patients are for their age, a tool like this could draw in much more data to make a better estimate, he added.
FaceAge, the machine learning tool created by researchers at Mass General Brigham, found that study subjects with cancer appeared five years older than their chronological age. The biological age of people without cancer was typically close to their actual age. And those who were categorized as older were more likely to die, either from cancer or other causes.
The researchers are not the first to find a link between facial and biological aging: A study in Denmark found that subjects who looked older than their chronological age tended to die earlier than their twins, and other studies have come to similar conclusions.
FaceAge was trained on a database of more than 56,000 images of people age 60 and older, mostly sourced from Wikipedia and the movie database I.M.D.B. The researchers then asked it to assess the age of study participants, most of whom had cancer, using photographs alone.
Doctors could one day use FaceAge to decide whether to provide different treatment depending on a patient's estimated biological age, said Dr. Raymond H. Mak, a radiation oncologist at Mass General Brigham who worked on the study.
Toni Feather, a 69-year-old hairdresser and a cancer patient under Dr. Mak's care, was one of the study participants who looked younger than her chronological age. Mrs. Feather, who lives in Upton, Mass., said Dr. Mak explained that her appearance — which was roughly 10 years younger than her age — could reflect biological resilience, which may have helped her withstand grueling treatments. (Mrs. Feather has undergone several rounds of surgery, chemotherapy and radiation for lung cancer, but she continues to work once a week and regularly cares for her young grandson.)
Preliminary data suggests that FaceAge goes beyond the visual markers of age we might look to, like wrinkles, gray hair or baldness, and instead flags less obvious factors like hollowing of the temples (which reflects a loss of muscle mass) and the prominence of the skin folds on either side of the mouth, Dr. Mak said.
The authors of the study hope to eventually commercialize the technology and create a product that could be used in doctor's offices. They plan to file for a patent once the technology is more developed.
The current version of the tool has limitations. It was primarily trained on white faces, Dr. Mak said, so it could work differently for people with different skin tones. And it isn't clear to what extent modifications like plastic surgery, makeup, lighting or the angle of the face could affect the results.
And while biological aging can be accelerated by a number of factors, like stress, pregnancy, smoking, drinking alcohol and even extreme heat, some of these changes can be reversible — and it's not clear if the tool would pick up those changes over time.
Experts in medical ethics also have concerns.
'I'd be very worried about whether this tool works equally well for all populations, for example women, older adults, racial and ethnic minorities, those with various disabilities, pregnant women and the like,' said Jennifer E. Miller, the co-director of the program for biomedical ethics at Yale University.
She and others in the field also wondered whether the tool might be used to justify denying insurance coverage or medical treatment.
Dr. Mak and other researchers who worked on the study have had reservations, too. 'We're really concerned about potential misuse of technology in general,' he said. However, he added, the researchers felt the tool would be more helpful than harmful — and it could be used to support, but not replace, clinicians' judgment.
It's unclear whether FaceAge's results will be more accurate, more scalable or cheaper than the results from existing tools for estimating biological age, said Daniel Belsky, a Columbia University epidemiologist and associate professor who co-led the development of DunedinPACE, a widely used epigenetic clock.
'There's a long way between where we are today and actually using these tools in a clinical setting,' Dr. Belsky said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 19, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-identify targets and discover first-in-class or best-in-class drug candidates using XtalPi's proprietary AI-driven drug discovery platform. The XtalPi platform combines the speed and generative power of AI with the accuracy of its robotic lab-in-the-loop to accelerate drug discovery and vastly expand the explorable chemical space. This integrated workflow spans deep-learning-based molecule design, quantum physics and molecular dynamics simulations for predicting drug-target interactions, automated chemical synthesis, and experimental validation of candidate compounds' key pharmaceutical properties. Leveraging its expertise in immunology and inflammation as well as its experience in small molecule drug development, Dong-A ST will actively participate throughout the entire R&D process—including candidate validation, efficacy and safety testing, and the formulation of preclinical and clinical development strategies. The company also plans to explore strategies for pipeline expansion and assess commercialization potential. Through this partnership, Dong-A ST aims to strengthen its pipeline in the immunology and inflammation space and expand its R&D scope beyond small molecule therapeutics into areas such as targeted protein degradation (TPD), biologics, antibody-drug conjugates (ADC), and gene therapies. John Wang, Senior Vice President of Drug Discovery at XtalPi, stated: "The combination of Dong-A ST's extensive expertise and XtalPi's proven AI-robotics platform is well-positioned to translate scientific innovation into competitive precision medicines. Together, we aim to rapidly discover and rigorously validate novel drug candidates across multiple modalities to unlock unique market opportunities, and deliver transformative therapies for global patients." Jae-Hong Park, Head of R&D at Dong-A ST, remarked, "This collaboration marks a pivotal step in expanding Dong-A ST's R&D capabilities," adding, "By leveraging synergies with XtalPi's AI platform, we expect to accelerate the development of next-generation treatments for immune and inflammatory diseases." Meanwhile, both Dong-A ST and XtalPi operate open innovation offices in Boston, USA. This geographic proximity will facilitate closer and more efficient collaboration throughout the drug discovery process. About Dong-A ST Dong-A ST Co., Ltd. ( was established in 1932 and is a leading Korean pharmaceutical company engaged in the development, manufacturing, and commercialization of ethical drugs, biosimilars, medical devices, and diagnostics. Its key products include Stillen (gastritis), Zydena (erectile dysfunction), Motilitone (functional dyspepsia), and Imuldosa (ustekinuma biosimilar). Leveraging strong R&D capabilities and a history of innovation, Dong-A ST is expanding its pipeline in immunology, inflammation, neurological disease, metabolic diseases, and oncology, while advancing into new modalities such as biologics, ADCs, TPD, and gene therapies. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc. Sign in to access your portfolio

CNN
25 minutes ago
- CNN
FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination
Federal agencies Food & healthFacebookTweetLink Follow The US Food and Drug Administration on Tuesday urged the public not to eat certain bags of frozen raw shrimp sold at Walmart, citing concerns about unsanitary conditions and radioactive contamination found in shipments from the same supplier. The FDA said that a radioactive isotope, cesium-137, was detected in a sample of breaded shrimp detained at US ports – in Los Angeles, Houston, Savannah, and Miami – from an Indonesian supplier named BMS Foods. Those contaminated shipments never reached the US market. However, because Walmart's raw frozen shrimp came from the same supplier – and the agency said it 'appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137' – officials advised consumers to avoid eating them. The levels of cesium detected – about 68 becquerels per kilogram – were well below the FDA's intervention level of 1,200 Bq/kg. Still, regulators issued the advisory out of caution, citing the potential risks of cancer from long-term, low-dose exposure and problems at the supplier's facility. The advisory applies to 2-pound Great Value bags of white vannamei shrimp, all carrying a best-by date of March 15, 2027. They were distributed to Walmart stores in at least 13 states: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. The agency is advising consumers who purchased the shrimp to throw it away or return it, and, said an investigation is ongoing in conjunction with Indonesian seafood regulatory authorities. Walmart confirmed to CNN that it 'immediately recalled the product from impacted stores.' CNN has also reached out to the supplier for comment.

CNN
25 minutes ago
- CNN
FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination
The US Food and Drug Administration on Tuesday urged the public not to eat certain bags of frozen raw shrimp sold at Walmart, citing concerns about unsanitary conditions and radioactive contamination found in shipments from the same supplier. The FDA said that a radioactive isotope, cesium-137, was detected in a sample of breaded shrimp detained at US ports – in Los Angeles, Houston, Savannah, and Miami – from an Indonesian supplier named BMS Foods. Those contaminated shipments never reached the US market. However, because Walmart's raw frozen shrimp came from the same supplier – and the agency said it 'appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137' – officials advised consumers to avoid eating them. The levels of cesium detected – about 68 becquerels per kilogram – were well below the FDA's intervention level of 1,200 Bq/kg. Still, regulators issued the advisory out of caution, citing the potential risks of cancer from long-term, low-dose exposure and problems at the supplier's facility. The advisory applies to 2-pound Great Value bags of white vannamei shrimp, all carrying a best-by date of March 15, 2027. They were distributed to Walmart stores in at least 13 states: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. The agency is advising consumers who purchased the shrimp to throw it away or return it, and, said an investigation is ongoing in conjunction with Indonesian seafood regulatory authorities. Walmart confirmed to CNN that it 'immediately recalled the product from impacted stores.' CNN has also reached out to the supplier for comment.



